Novartis Ag (NVS) Notes Payables (2017 - 2025)
Novartis Ag (NVS) has disclosed Notes Payables for 9 consecutive years, with $682.0 million as the latest value for Q4 2025.
- Quarterly Notes Payables rose 6.23% to $682.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $682.0 million through Dec 2025, up 6.23% year-over-year, with the annual reading at $682.0 million for FY2025, 6.23% up from the prior year.
- Notes Payables hit $682.0 million in Q4 2025 for Novartis Ag, up from $642.0 million in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $899.0 million in Q4 2021 to a low of $624.0 million in Q4 2023.
- Historically, Notes Payables has averaged $742.0 million across 5 years, with a median of $682.0 million in 2025.
- Biggest five-year swings in Notes Payables: fell 27.69% in 2023 and later rose 6.23% in 2025.
- Year by year, Notes Payables stood at $899.0 million in 2021, then decreased by 4.0% to $863.0 million in 2022, then decreased by 27.69% to $624.0 million in 2023, then increased by 2.88% to $642.0 million in 2024, then grew by 6.23% to $682.0 million in 2025.
- Business Quant data shows Notes Payables for NVS at $682.0 million in Q4 2025, $642.0 million in Q4 2024, and $624.0 million in Q4 2023.